AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

GSK · NYSE · Drug Manufacturers - General

GSK (ADR) (GSK)

Develops specialty medicines and vaccines through immune-system science and advanced technologies.

$50.53

vs last close−0.55 (−1.08%)

In millions of USD, except per-share figures · converted from GBP at the latest rate

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	10,881	10,754	9,834	10,530	10,701	10,841	10,038	10,666	11,415	11,510	10,189	11,231
Cost of revenue	3,034	3,229	2,631	2,834	3,201	3,418	2,587	2,892	3,016	3,549	2,504	3,026
Gross profit	7,847	7,525	7,203	7,696	7,499	7,423	7,451	7,774	8,400	7,961	7,685	8,205
	5,244	6,759	5,213	5,497	7,247	6,494	4,492	5,073	4,936	5,950	4,622	7,562
Research & development	2,104	2,734	1,915	1,973	1,949	2,713	1,953	2,703	2,256	3,139	2,260	4,629
	3,067	3,577	2,787	3,292	5,075	3,557	2,765	2,858	2,990	3,525	2,830	2,941
General & administrative	3,067	3,577	2,787	3,292	5,075	3,557	2,765	2,858	2,990	3,525	2,830	2,941
Other expenses	73	449	510	232	223	224	−226	−489	−310	−713	−467	−8
Operating income	2,603	765	1,990	2,198	252	930	2,960	2,702	3,463	2,011	3,063	642
	−211	−259	−180	−202	−167	−178	−144	−182	−183	−743	−199	−170
Interest income	32	48	43	32	43	−68	72	67	35	0	29	77
Interest expense	243	368	222	232	208	192	216	246	223	232	223	243
Other non-operating income	−32	52	−41	−31	−41	−15	−72	−64	−40	510	−24	−73
Income before tax	2,392	506	1,810	1,997	85	752	2,815	2,520	3,280	1,269	2,864	473
Income tax expense	343	−25	366	255	−1	83	449	322	417	298	407	−266
Net income from continuing operations	2,049	532	1,444	1,742	87	669	2,367	2,198	2,864	971	2,456	739
Net income	1,955	467	1,397	1,567	−77	553	2,169	1,927	2,689	849	2,320	581
EPS, basic	$0.96	$0.23	$0.69	$0.77	−$0.04	$0.27	$1.07	$0.96	$1.34	$0.43	$1.15	$0.29
EPS, diluted	$0.96	$0.23	$0.67	$0.75	−$0.04	$0.27	$1.04	$0.93	$1.31	$0.41	$1.15	$0.29
Weighted average shares, basic	2,028	2,028	2,035	2,040	2,040	2,041	2,044	2,032	2,017	2,010	2,012	2,007
Weighted average shares, diluted	2,056	2,059	2,057	2,061	2,040	2,073	2,069	2,055	2,051	2,043	2,037	2,031
EBITDA	3,408	1,545	2,765	3,083	1,564	1,495	4,131	4,314	4,489	2,547	3,705	3,774
Depreciation & amortization	773	832	733	853	1,270	550	1,099	1,548	986	1,045	618	3,059
EBIT	2,635	713	2,031	2,229	294	944	3,032	2,766	3,503	1,501	3,087	716